5 February 2007

Contents

Antiretrovirals

• Pharmacokinetic study of Triomune-40 in Malawi: higher d4T exposure suggests importance of using lower dose formulations of d4T

• GSK stops development of brecanavir

• FDA analysis of predicted responses to tipranavir/r

• Important changes to US prescribing information for efavirenz

• Changes to US product label for T-20 (enfuvirtide)

Treatment access

• Wall Street Journal examines reason Abbott increased price of ritonavir

• Access to treatment in the USA: waiting list for ARVs in South Carolina

• Royalty-free license granted for development of tenofovir and topical microbicide

• Novartis test case in India threatens the ARV pharmacy of the developing world

• Thailand issues compulsory license to manufacture lopinavir/r: WHO criticised for challenging this essential access to treatment

• Global Fund Board selects new executive director

Women's health

• Limited impact of immunosuppression and HAART on the incidence of cervical squamous intraepithelial lesions in HIV positive women

• Hormonal contraception and the risk of HIV acquisition

Pregnancy

• Response to nevirapine containing HAART following single dose nevirapine for PMTCT

Paediatric care

• WHO paediatric recommendations

• Masking the flavour of antiretrovirals in Thai children

Opportunistic infections and complications

• Elevated risk of lung cancer among people with AIDS

Hepatitis coinfection

• Increased prevalence of cardiovascular disease among HIV-positive individuals coinfected with hepatitis C

Vaccines and microbicides

• Two phase III HIV microbicide trials stopped due to increased transmission

On the web

• Presentations from satellite sessions at ICCAC

• Full text articles online

• TB coinfection

• IAVI report: 2006 Year in Review